Research programme: complement inhibitors - AvanirAlternative Names: Complement inhibitors research programme - Avanir
Latest Information Update: 15 Mar 2006
At a glance
- Originator Avanir Pharmaceuticals
- Mechanism of Action Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 15 Mar 2006 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 09 Apr 2001 Preclinical development for Inflammation in USA (Unknown route)